SEC Filing Summary
Issuer and period: The supplied filing is Check-Cap Ltd.’s audited annual report on Form 20-F for the fiscal year ended December 31, 2022, filed March 31, 2023. It is not a filing for “Mbody AI Ltd.” or a standalone 2022 fourth quarter report. Financial statements are prepared under U.S. GAAP and amounts below are in U.S. dollars.
Business context
Check-Cap is a clinical-stage medical diagnostics company developing C-Scan, an ingestible, ultra-low-dose X-ray capsule system intended to screen for colorectal polyps without bowel cleansing or sedation. The system has not been commercialized, and the company reported no revenue since inception. Its business depends on clinical results, regulatory approvals, manufacturing scale-up, financing, and eventual market adoption.
Financial results and liquidity
| Metric | 2022 | 2021 | Change or context |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue since inception |
| Research and development expense, net | $14.3 million | $12.3 million | Increased 15.6% |
| General and administrative expense | $5.8 million | $5.0 million | Increased 15.9% |
| Operating loss | $20.0 million | $17.3 million | Loss widened 15.7% |
| Finance income, net | $0.9 million | $0.1 million | Primarily higher interest income on deposits |
| Net loss | $19.1 million | $17.2 million | Loss increased $1.9 million |
| Net loss per share | $3.37 | $4.14 | Post-reverse-split basis; weighted average shares rose |
| Net cash used in operating activities | $18.7 million | $16.3 million | Cash use increased |
| Net cash used in investing activities | $12.5 million | $16.0 million | Mostly short-term bank deposits, not operating investment |
| Net cash provided by financing activities | $8.9 million | $51.0 million | 2022 mainly reflects the March registered direct offering |
At year-end 2022, total assets were $45.4 million, including $4.1 million of cash and cash equivalents, $0.4 million of restricted cash, and $37.6 million of short-term bank deposits. Current assets totaled $42.6 million and current liabilities were $3.4 million. Shareholders’ equity was $41.3 million; accumulated deficit was $127.3 million. The company reported no outstanding borrowings. Its cash, cash equivalents, restricted cash, and short-term deposits totaled approximately $42.1 million.
There is no meaningful revenue margin to assess. Management expects continuing operating losses and negative operating cash flow. It reported $8.85 million of net proceeds from the March 2022 offering, which issued 1,000,000 shares and warrants to purchase up to 750,000 shares. The company effected a 1-for-20 reverse share split in November 2022. Year-end shares outstanding were 5,844,463.
Material developments and outlook
- After reviewing calibration-study data, management concluded that efficacy results did not meet its threshold to begin the powered second part of the U.S. pivotal study. That stage, previously expected to start in mid-2023, was temporarily postponed. The company planned further data analysis, continued calibration studies at a slower pace, and a proposed study-protocol amendment for FDA review; approval and trial commencement are not assured.
- The first part of the U.S. pivotal study began in May 2022. By the filing, enrollment was 17 U.S. average-risk patients; the Israeli calibration study had enrolled more than 300. Management cited slower U.S. recruitment partly due to state-specific licensing requirements for the X-ray technology.
- The FDA had approved the company’s IDE for the planned pivotal study, but C-Scan had not received FDA marketing clearance or approval. The company’s strategy was to seek direct de novo classification after successful pivotal-study completion; FDA could instead require the more demanding PMA route.
- C-Scan held a CE certificate valid through December 1, 2026, and Israeli marketing authorization valid through December 31, 2024. These authorizations do not establish U.S. approval or guarantee commercial sales.
- Management was implementing cost reductions and estimated that available cash would fund ongoing operations and plans into the fourth quarter of 2024. This is a management estimate dependent on trial timing, costs, regulatory requirements, and other factors; additional financing will be needed to complete development and commercialization.
- Key risks include persistent losses and financing needs; uncertain clinical efficacy and trial timing; dependence on one product; regulatory and reimbursement uncertainty; limited manufacturing capacity and single-source suppliers; radioactive-material handling and disposal requirements; and political, economic, and security conditions in Israel. The company also identified a Russian source for enriched X-ray isotope material and potential supply disruption risks.
- Israeli Innovation Authority grants create contingent royalty and other obligations. At year-end, the company disclosed approximately $6.2 million of contingent IIA obligations, including interest, payable from qualifying product revenues; it had paid no IIA royalties. A separate $94,000 provision related to ASIC royalties.
- The company believed it was a passive foreign investment company (PFIC) for 2022 and could be one in 2023, creating potential U.S. tax consequences for U.S. investors. No material litigation was reported.
Most important facts to verify
- Confirm the issuer identity: this filing is for Check-Cap Ltd., ticker CHEK, not Mbody AI Ltd.
- Review subsequent clinical data and FDA communications: the pivotal study’s powered stage was postponed because calibration efficacy did not meet management’s goal.
- Check updated cash, cash burn, cost-reduction execution, and financing plans against the stated runway into Q4 2024.
- Track regulatory progress, including any FDA-approved protocol amendments, U.S. site licensing, and the eventual clearance or approval pathway.
- Assess potential dilution from future equity financings and outstanding warrants, alongside the effects of the reverse split.
- Review the audited financial statements and notes for cash restrictions, grant-related obligations, supplier exposures, and PFIC tax disclosures. The auditor issued an unqualified opinion on the financial statements; it did not provide an internal-control attestation.